CNS Pharmaceuticals, Inc. Earnings Per Share (Basic)
CNS Pharmaceuticals, Inc. (CNSP) reported Earnings Per Share (Basic) of -$0.38 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.38.
- CNS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$7.30.
- CNS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was $16.09, a 87.65% decline year-over-year.
- CNS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$5.76.
- CNS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$35.75.
- CNS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$466.89.
- CNS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$12509.11.
- CNS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$11.22.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.38 10-Q · filed 2026-08-12 | -$1.99 10-Q · filed 2026-08-12 | $0.87 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-08-21 | ||||
| 2026-03-31 | -$7.30 10-Q · filed 2026-05-14 | $7.66 derived: net income ÷ weighted average shares · filed 2026-08-21 | $2.80 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$1.17 derived: net income ÷ weighted average shares · filed 2026-08-21 | ||||
| 2025-12-31 | $16.09 derived: net income ÷ weighted average shares · filed 2026-08-21 | $11.36 derived: net income ÷ weighted average shares · filed 2026-08-21 | $8.33 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$35.75 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$5.76 10-Q · filed 2025-11-14 | -$12.04 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$25.60 10-Q · filed 2025-11-14 | $5.69 derived: net income ÷ weighted average shares · filed 2026-08-21 | ||||
| 2025-06-30 | -$6.42 10-Q · filed 2026-08-12 | -$22.35 10-Q · filed 2026-08-12 | $21.80 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$3.40 derived: net income ÷ weighted average shares · filed 2026-08-21 | ||||
| 2025-03-31 | -$18.93 10-Q · filed 2026-05-14 | -$1.58 10-Q · filed 2025-05-15 | $46.51 derived: net income ÷ weighted average shares · filed 2026-08-21 | $14.94 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$8.71 derived: net income ÷ weighted average shares · filed 2026-08-21 | |||
| 2024-12-31 | $130.33 derived: net income ÷ weighted average shares · filed 2026-08-21 | $96.12 derived: net income ÷ weighted average shares · filed 2026-08-21 | $83.56 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$466.89 10-K · filed 2026-03-31 | -$38.87 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$153.20 10-Q · filed 2025-11-14 | -$0.25 10-Q · filed 2024-11-14 | -$437.24 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$927.76 10-Q · filed 2025-11-14 | -$1.54 10-Q · filed 2024-11-14 | -$46.44 derived: net income ÷ weighted average shares · filed 2026-08-21 | ||
| 2024-06-30 | -$4049.20 10-Q · filed 2025-08-14 | -$6.72 10-Q · filed 2024-08-14 | -$13294.31 10-Q · filed 2025-08-14 | -$22.08 10-Q · filed 2024-08-14 | -$116.84 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$107.89 derived: net income ÷ weighted average shares · filed 2026-08-21 | ||
| 2024-03-31 | -$1020.48 10-Q · filed 2025-05-15 | -$0.41 10-Q · filed 2024-05-15 | -$104.25 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$151.66 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$188.30 derived: net income ÷ weighted average shares · filed 2026-08-21 | |||
| 2023-12-31 | -$69.50 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$162.31 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$452.93 derived: net income ÷ weighted average shares · filed 2026-08-21 | -$12509.11 10-K · filed 2025-03-31 | -$5.00 10-K · filed 2024-04-01 | |||
| 2023-09-30 | -$54.14 10-Q · filed 2024-11-14 | -$1.08 10-Q · filed 2023-11-14 | -$106.08 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$202.48 10-Q · filed 2024-11-14 | -$4.05 10-Q · filed 2023-11-14 | -$20.96 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||
| 2023-06-30 | -$51.86 10-Q · filed 2024-08-14 | -$1.04 10-Q · filed 2023-08-14 | -$154.70 10-Q · filed 2024-08-14 | -$3.10 10-Q · filed 2023-08-14 | -$12.19 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$14.58 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||
| 2023-03-31 | -$2.59 10-Q · filed 2024-05-15 | -$5.94 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$8.56 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$11.26 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2022-12-31 | -$3.46 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$6.07 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$8.76 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$11.22 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$2.56 10-Q · filed 2023-11-14 | -$0.09 10-Q · filed 2022-11-10 | -$5.23 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$7.67 10-Q · filed 2023-11-14 | -$0.25 10-Q · filed 2022-11-10 | $0.76 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||
| 2022-06-30 | -$2.67 10-Q · filed 2023-08-14 | -$0.09 10-Q · filed 2022-08-12 | -$5.11 10-Q · filed 2023-08-14 | -$0.16 10-Q · filed 2022-08-12 | $0.42 derived: net income ÷ weighted average shares · filed 2023-11-14 | $1.25 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||
| 2022-03-31 | -$2.44 10-Q · filed 2023-05-15 | $0.18 derived: net income ÷ weighted average shares · filed 2023-11-14 | $0.68 derived: net income ÷ weighted average shares · filed 2023-11-14 | $2.82 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||||
| 2021-12-31 | $0.04 derived: net income ÷ weighted average shares · filed 2023-03-31 | $0.30 derived: net income ÷ weighted average shares · filed 2023-03-31 | $1.54 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$16.50 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$0.14 10-Q · filed 2022-11-10 | -$0.29 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.43 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | -$0.15 10-Q · filed 2022-08-12 | -$0.30 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |